SEC Form 4Coverage since Aug 12, 2025
$DNLI insider trading
Over the last 12 months, Denali Therapeutics insiders reported no purchases and 2 sales totaling $92K across SEC Form 4 filings. 50% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $92K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 50% pre-arranged plans
Side
Price · $DNLI · 12Mvia TradingView
Top insiders · 12m
Schuth Alexander O.COFO and Secretary1× · $40K
Ho CaroleChief Medical Officer1× · $52K
All insider trades
2 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 13, 2025 | Ho CaroleChief Medical Officer · O | ▼ Sale | 3,743 | $13.81 | $52K | -1.7% | plan · 2 tranches |
| Aug 12, 2025 | Schuth Alexander O.COFO and Secretary · O | ▼ Sale | 2,937 | $13.58 | $40K | -1.2% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $DNLI feed.